Methodologies for Anti-HLA antibody screening in patients awaiting kidney transplant: A comparative study

Experimental and Clinical Transplantation

Volumn 9, Issue 6, 2011, Pages 381-386

  Minucci, Pellegrino B ^a   Grimaldi, Vincenzo ^a   Casamassimi, Amelia ^a   Cacciatore, Francesco ^b   Sommese, Linda ^a   Picascia, Antonietta ^a   Resse, Marianna ^a   Sabia, Chiara ^a   Russo, Adolfo ^a   Napoli, Claudio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS   (Italy)

Author keywords

CDC; ELISA; Flow PRA; HLA antibody. class I and class II antibodies; Luminex

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 1 ANTIBODY; HLA ANTIGEN CLASS 2 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIGEN ANTIBODY REACTION; ARTICLE; COMPARATIVE STUDY; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT DEPENDENT CYTOTOXICITY METHOD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL PROCEDURES; KIDNEY GRAFT; MAJOR CLINICAL STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEROLOGY;

ADOLESCENT; ADULT; AGED; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; ITALY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; WAITING LISTS; YOUNG ADULT;

EID: 83455242890     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Porter KA. The effects of antibodies on human renal allografts. Transplant Proc. 1976;8(2):189-192.
2. Stastny P, Salvador IM, Lavingia B. Evaluation of the highly sensitized transplant recipient. Pediatr Nephrol. 2011. [Epub ahead of print].
3. Kissmeyer-Nielsen F, Olse S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966;2(7465):662-665.
4. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. New Engl J Med. 1969;280(14):735-739.
5. Gloor J, Stegall MD. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol. 2010;6(5):297-306.
6. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964;204:998-1000.
7. Zeevi A, Girnita A, Duquesnoy R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res. 2006;36(1-3):255-264.
8. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol. 2009;70(8):580-583.
9. Batal I, Zeevi A, Lunz JG 3rd, et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med. 2010;34(10):1534-1540.
10. Gebel HM, Bray RA, Ruth JA, et al. Flow PRA to detect clinically relevant HLA antibodies. Transplant Proc. 2001;33(1-2):477.
11. Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom. 2007;72(6):465-471.
12. Lee PC, Ozawa M, Hung CJ, Lin YJ, Chang SS, Chou TC. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Transplant Proc. 2009;41(1):95-98.
13. Mansour I, Messaed C, Azoury M, Klayme S, Naaman R. Panel-reactive antibodies using complement-dependent cytotoxicity, flow cytometry, and ELISA in patients awaiting renal transplantation or transplanted patients: a comparative study. Transplant Proc. 2001;33(5):2844-2847.
14. Poli F, Cardillo M, Scalamogna M. Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol. 2009;70(8):631-635.
15. Muro M, Llorente S, Marín L, et al. Acute vascular rejection mediated by HLA antibodies in a cadaveric kidney recipient: discrepancies between FlowPRA, ELISA and CDC vs luminex screening. Nephrol Dial Transplant. 2005;20(1):223-226.
16. Billen EV, Christiaans MH, van den Berg-Loonen EM. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants. Tissue Antigens. 2009;74(3):205-212.
17. Chapman JR, Taylor CJ, Ting A, Miach PJ, Chapman JR, Morris PJ. Immunoglobulin Class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation. 1986;42(6):608-613.
18. Roelen DL, van Bree J, Witvliet MD, et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Transplantation. 1994;57(9):1388-1392.
19. Tait BD, Hudson F, Cantwell L, et al. Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton). 2009;14(2):247-254.
20. Süsal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation. 2011;91(8):883-887.